Clinical Research Directory

DEL-1 and Thromboxane A2 in Diabetic Nephropathy Patients

Sponsor: Aswan University

Summary

Diabetic nephropathy is one of the most common microvascular complications of diabetes mellitus and a leading cause of chronic kidney disease. Inflammation and platelet activation are believed to play a significant role in its pathogenesis and progression. Developmental endothelial locus-1 (DEL-1) is an anti-inflammatory protein that regulates leukocyte adhesion and endothelial function, while thromboxane A2 is a marker of platelet activation and contributes to vascular dysfunction. This study aims to evaluate serum levels of DEL-1 and thromboxane A2, and their relationship with platelet count in patients with diabetic nephropathy. Additionally, the study investigates the correlation between these biomarkers and disease severity. This observational cross-sectional study will be conducted on 80 participants, including patients with diabetic nephropathy and healthy controls, to explore the potential role of these biomarkers in disease progression and their possible use as diagnostic or prognostic indicators.

Official title: Developmental Endothelial Locus-1 Serum Level and Its Relation With Thromboxane A2 and Platelet Count in Patients With Diabetic Nephropathy

Key Details

Conditions

Interventions